Study of AUY922 in Metastatic Pancreatic Cancer Who Are Resistant to First Line Chemotherapy

NCT01484860 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

15

Enrollment

OTHER

Sponsor class

Conditions

Adenocarcinoma of the Pancreas
Metastatic Disease

Interventions

DRUG: AUY922

Sponsor

University Health Network, Toronto

Collaborators

[object Object]